Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objective: This study aims to identify the latent profiles of resilience among patients with colorectal cancer and an enterostomy, analyze potential influencing factors, and explore the differences in patient activation across different profiles.
Methods: This cross-sectional study recruited a total of 375 patients with colorectal cancer and an enterostomy from three large public hospitals in Chongqing, China, between August 2024 and January 2025 using convenience sampling. Questionnaires used include sociodemographic information, a 10-item Connor-Davidson Resilience Scale, and a Patient Activation Measure. Latent profile analysis, univariate analysis, and multiple logistic regression analysis were used to explore resilience profiles and identify interindividual variability. Additionally, one-way analysis of variance (ANOVA) and the least significant difference (LSD) method were applied to analyze multiple comparisons between resilience profiles and patient activation.
Results: Following data analyses, the resilience was categorized into three latent profiles: the low resilience-pressure sensitive group (25.8%), moderate resilience-balanced group (38.4%), and high resilience-growth consolidation group (35.8%). Gender, medical insurance types, per capita monthly household income, stoma-related complications, and the duration of stoma establishment were identified as predictors of the participants' latent profiles of resilience. Additionally, significant differences in patient activation levels were observed across the three profiles.
Conclusions: Resilience in colorectal cancer patients with enterostomy exhibits significant individual variability and is influenced by multiple factors. Health care professionals should focus more on patients with lower resilience and develop targeted, personalized strategies as early as possible. Addressing these differences may offer new insights for improving patient activation.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12395505 | PMC |
| http://dx.doi.org/10.1016/j.apjon.2025.100768 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Inter-Assay Variability of TROP2 Immunohistochemistry in Triple-Negative Breast Cancer.
Mol Diagn Ther
September 2025
Division of Pathology, IEO, European Institute of Oncology IRCCS, Via G. Ripamonti 435, 20141, Milan, Italy.
Background And Objective: Sacituzumab govitecan, an anti-trophoblast cell surface antigen 2 (TROP2) antibody-drug conjugate, has been approved by both the US Food and Drug Administration and European Medicines Agency for patients with metastatic triple-negative breast cancer who have received two or more prior systemic therapies, including at least one of them for advanced disease. Although TROP2 evaluation is not required for patient selection, survival data from the ASCENT trial show improved response rates in patients with high TROP2 expression by immunohistochemistry. However, there is no standardized testing assay for these patients.
View Article and Find Full Text PDFDissolution of Once-Nightly Sodium Oxybate in Soft Foods and Alternative Liquid Reconstitution Vehicles.
Clin Ther
September 2025
Avadel Pharmaceuticals, Chesterfield, Missouri.
Purpose: Narcolepsy is a chronic neurologic disorder characterized by excessive daytime sleepiness (EDS) and can occur with or without cataplexy. Once-nightly sodium oxybate (ON-SXB) is approved for the treatment of cataplexy or EDS in patients 7 years of age or older with narcolepsy. ON-SXB contains both immediate-release and pH-dependent, controlled-release granules designed to be reconstituted in water and administered orally once at bedtime.
View Article and Find Full Text PDFUnraveling the nexus in the neuro-neoplastic progression of colorectal cancer: Potential role of β2-adrenergic receptor (β2-AR).
J Adv Res
September 2025
Department of Physiology and Biophysics, Weill Cornell Medicine-Qatar, Education City, Qatar Foundation, Doha P.O. Box 24144, Qatar. Electronic address:
Background: Studies on the interaction of cancer cells with other cells (fibroblasts, endothelial cells, and immune cells) of the tumor microenvironment (TME) have led to the development of many novel targeted therapies. More recently, the notion that neuronal cells of the TME could impact various processes supporting cancer progression has gained momentum. Tumor-associated neurons release neurotransmitters into the TME that, in turn, bind to specific receptors on different target cells, supporting cancer progression.
View Article and Find Full Text PDFNDUFS8 facilitates hepatocellular carcinoma growth by enhancing mitochondrial function and escaping HUWE1-dependent degradation.
Transl Oncol
September 2025
Department of General Surgery, Affiliated Zhangjiagang Hospital of Soochow University. Electronic address:
Background: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide. Although mitochondrial metabolism contributes to tumorigenesis, the specific roles of individual mitochondrial components remain unclear.NADH:ubiquinone oxidoreductase core subunit S8 (NDUFS8), a key subunit of mitochondrial complex I, has been implicated in non-hepatic malignancies, but its functional relevance in HCC is unknown.
View Article and Find Full Text PDFTargeting KCNN4 channels modulates microglial activation and apoptosis in a PD-relevant inflammatory model.
Biomed Pharmacother
September 2025
Department and Graduate Institute of Pharmacology, College of Pharmacy, National Defense Medical University, Taipei, Taiwan; Department of Pharmacy Practice, Tri-Service General Hospital, National Defense Medical University, Taipei, Taiwan; School of Pharmacy, College of Pharmacy, National Defense M
Parkinson's disease (PD) is characterized by chronic neuroinflammation and progressive dopaminergic neurodegeneration, driven primarily by the activation of microglia and associated apoptotic pathways. The intermediate-conductance calcium-activated potassium channel KCNN4 has recently emerged as a potential therapeutic target, yet its role in chronic neurodegenerative conditions remains underexplored. In this study, we investigated whether pharmacological inhibition of KCNN4 using TRAM-34 can modulate both inflammatory and apoptotic responses in an LPS-induced mouse model of PD.
View Article and Find Full Text PDF